Alpha Tau to Present Early Data from Glioblastoma Trial
Event summary
- Alpha Tau will discuss interim results from the first three patients treated in its U.S. REGAIN trial for recurrent glioblastoma on May 11, 2026.
- The trial aims to enroll up to ten patients with recurrent glioblastoma not amenable to surgical resection.
- Alpha DaRT technology uses radium-224 to deliver targeted alpha-irradiation to tumors.
- The primary objective is to evaluate the feasibility and safety of the treatment.
The big picture
Alpha Tau's interim data release comes at a critical juncture for the company as it seeks to validate its Alpha DaRT technology in a high-unmet-need indication like recurrent glioblastoma. The success of this trial could position Alpha Tau as a key player in targeted alpha-radiation therapy, potentially attracting more investment and partnerships. The broader oncology sector is watching closely, as innovative approaches to treating aggressive cancers like glioblastoma are in high demand.
What we're watching
- Clinical Efficacy
- How the interim results from the first three patients will impact the perceived efficacy of Alpha DaRT in treating recurrent glioblastoma.
- Regulatory Pathway
- Whether the early data will accelerate or impede the regulatory approval process for Alpha DaRT.
- Market Positioning
- The pace at which Alpha Tau can differentiate itself in the competitive landscape of cancer therapies.
Related topics